Figure 5From: Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection Mean change from baseline in a) EQ-5D valuation index values and b) EQ-5D VAS for all simeprevir/PR treatment groups combined vs placebo/PR in the PILLAR and ASPIRE studies. Back to article page